Garcia-Carretero Rafael, Ordoñez-Garcia Maria, Gil-Prieto Ruth, Gil-de-Miguel Angel
Internal Medicine Department, Mostoles University Hospital, Rey Juan Carlos University, 29835 Mostoles, Spain.
Hematology Department, Mostoles University Hospital, Rey Juan Carlos University, 29835 Mostoles, Spain.
J Clin Med. 2024 Sep 12;13(18):5400. doi: 10.3390/jcm13185400.
: Early reports suggest that hematological malignancy (HM) is a relevant risk factor for morbidity and mortality in COVID-19. We investigated the characteristics, outcomes, and risk factors for mortality in patients hospitalized with HM and COVID-19. : We conducted a retrospective, nationwide study using data from hospitalized patients that were provided by the Spanish Ministry of Health including all patients admitted to a Spanish hospital from 2020 to 2022 with a COVID-19 diagnosis. A descriptive analysis and correlational analyses were conducted. Logistic regression was used to assess mortality in these patients and to calculate odds ratios (ORs). : We collected data on 1.2 million patients with COVID-19, including 34,962 patients with HMs. The incidence of hospitalization for patients with HMs was 5.8%, and the overall mortality rate was higher than for patients without HMs (19.8% versus 12.7%, = 0.001). Mortality rates were higher for patients with lymphomas, multiple myelomas, and leukemias than for those with myeloproliferative disorders. Having HMs was a risk factor for mortality, with OR = 1.7 (95% CI 1.66-1.75, = 0.001). By subtype, non-Hodgkin lymphomas were the highest risk factor for mortality (OR = 1.7), followed by leukemias (OR = 1.6), Hodgkin lymphomas (OR = 1.58), and plasma cell dyscrasias (OR = 1.24). : This study identifies the different clinical profiles of patients with HMs who are at a high risk for mortality when hospitalized with COVID-19. As members of a vulnerable population, these patients deserve special prophylactic and therapeutic measures to minimize the effects of SARS-CoV-2 infection.
早期报告表明，血液系统恶性肿瘤（HM）是新冠病毒病（COVID-19）发病和死亡的一个相关风险因素。我们调查了合并HM和COVID-19住院患者的特征、结局及死亡风险因素。
我们利用西班牙卫生部提供的住院患者数据进行了一项全国性回顾性研究，纳入了2020年至2022年期间在西班牙医院确诊COVID-19的所有患者。进行了描述性分析和相关性分析。采用逻辑回归评估这些患者的死亡率并计算比值比（OR）。
我们收集了120万例COVID-19患者的数据，其中包括34962例HM患者。HM患者的住院率为5.8%，总体死亡率高于非HM患者（19.8%对12.7%，P = 0.001）。淋巴瘤、多发性骨髓瘤和白血病患者的死亡率高于骨髓增殖性疾病患者。患有HM是死亡的一个风险因素，OR = 1.7（95%CI 1.66 - 1.75，P = 0.001）。按亚型划分，非霍奇金淋巴瘤是最高的死亡风险因素（OR = 1.7），其次是白血病（OR = 1.6）、霍奇金淋巴瘤（OR = 1.58）和浆细胞异常（OR = 1.24）。
本研究确定了合并COVID-19住院时死亡风险高的HM患者的不同临床特征。作为弱势群体的成员，这些患者应得到特殊的预防和治疗措施，以尽量减少严重急性呼吸综合征冠状病毒2感染的影响。
